Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420379 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
A Phase 2 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02420379 is a Phase 2 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT02420379, a Phase 2 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Interventions
- DRUG eteplirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-06-30 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420379
The ClinicalTrials.gov registry entry for NCT02420379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eteplirsen is the first listed.
NCT02420379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420379 about?
NCT02420379 is a clinical study titled "Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy". This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
What is the current status of trial NCT02420379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-06-30. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT02420379?
The interventions under investigation include: eteplirsen (DRUG).
Who is sponsoring clinical trial NCT02420379?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.